Aiolos/IKZF3 Antibody - BSA Free

IKZF3 encodes a member of the Ikaros family of zinc-finger proteins. Three members of this protein family (Ikaros, Aiolos and Helios) are hematopoietic-specific transcription factors involved in the regulation of lymphocyte development. This gene product is a transcription factor that is important in the regulation of B lymphocyte proliferation and differentiation. Both Ikaros and Aiolos can participate in chromatin remodeling. Regulation of gene expression in B lymphocytes by Aiolos is complex as it appears to require the sequential formation of Ikaros homodimers, Ikaros/Aiolos heterodimers, and Aiolos homodimers. At least six alternative transcripts encoding different isoforms have been described. [provided by RefSeq]

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

We have publications tested in 1 confirmed species: Human.

We have publications tested in 3 applications: ICC/IF, IF/IHC, WB.

Showing Publications 1 - 10 of 14. Show All 14 Publications. Collapse Publications.

Publications using NBP2-24495	Applications	Species
Jochem M, Schrempf A, Wagner LM et Al. Degradome analysis to identify direct protein substrates of small-molecule degraders Cell Chem Biol 2024-11-07 [PMID: 39536762]
Zou Y, Liu B, Li L Et al. IKZF3 deficiency potentiates chimeric antigen receptor T cells targeting solid tumors Cancer letters 2021-10-20 [PMID: 34687790] (WB)	WB
Chen H, Liu J, Kaniskan HU Et al. Folate-Guided Protein Degradation by Immunomodulatory Imide Drug-Based Molecular Glues and Proteolysis Targeting Chimeras Journal of medicinal chemistry 2021-08-26 [PMID: 34378936]
Barankiewicz J, Szumera-Cieckiewicz A, Salomon-Perzynski A et al. The CRBN, CUL4A and DDB1 Expression Predicts the Response to Immunomodulatory Drugs and Survival of Multiple Myeloma Patients Journal of Clinical Medicine 2021-06-18 [PMID: 34207079] (IF/IHC, Human)	IF/IHC	Human
Walker, Z J, Idler, B Et al. Exploiting Protein Translation Dependence in Multiple Myeloma with Omacetaxine-Based Therapy. Clin Cancer Res 2021-02-01 [PMID: 33109736] (ICC/IF, Human)	ICC/IF	Human
Wang Z, Zhou G, Risu N et al. Lenalidomide Enhances CAR-T Cell Activity Against Solid Tumor Cells Cell Transplant 2020-09-24 [PMID: 32967454] (WB, Human)	WB	Human
Liu J, Chen H, Ma L et al. Light-induced control of protein destruction by opto-PROTAC Sci Adv 2020-02-01 [PMID: 32128407] (WB, Human)	WB	Human
Kim E, Ten Hacken E, Sivina M, et al. The BET inhibitor GS-5829 targets chronic lymphocytic leukemia cells and their supportive microenvironment Leukemia 2019-12-20 [PMID: 31862959]
Zhu YX, Shi CX, Bruins LA et al. Identification of lenalidomide resistance pathways in myeloma and targeted resensitization using cereblon replacement, inhibition of STAT3 or targeting of IRF4 Blood Cancer J 2019-02-11 [PMID: 30741931] (WB, Human)	WB	Human
Costa F, Vescovini R, Bolzoni M et al. Lenalidomide increases human dendritic cell maturation in multiple myeloma patients targeting monocyte differentiation and modulating mesenchymal stromal cell inhibitory properties Oncotarget 2017-08-08 [PMID: 28881793] (WB, Human)	WB	Human
Uehara T, Minoshima Y, Sagane K et al. Selective degradation of splicing factor CAPERalpha by anticancer sulfonamides. Nat. Chem. Biol. 2017-04-24 [PMID: 28437394]
Nguyen TV, Li J, Lu CJ et al. p97/VCP promotes degradation of CRBN substrate glutamine synthetase and neosubstrates. Proc. Natl. Acad. Sci. U.S.A. 2017-03-20 [PMID: 28320958] (WB, Human)	WB	Human
Gao S, Geng C, Song T et al. Activation of c-Abl kinase potentiates the anti-myeloma drug lenalidomide by promoting DDA1 recruitment to the CRL4 ubiquitin ligase J. Biol. Chem 2017-01-13 [PMID: 28087699]
Zhu YX, Braggio E, Shi CX et al. Identification of cereblon binding proteins and relationship with response and survival following pomalidomide and dexamethasone in multiple myeloma. Blood. 2014-06-09 [PMID: 24914135] (WB, Human) Details: Figs 3 & 5: IKZF1, IKZF3 or cerebron (CRBN), lentiviral infected human myeloma cell lines (HMCLs) and infected HMCLs treated with IKZF1, IKZF3 or CRBN ShRNAs, respecitvely. The specificity of the IKZF3 pAb was validated in IKZF3-infected HMCLs and in IKZF3-shRNA infected cells by WB (Figs 3 & 5). The IKZF3 pAb recognized IKZF3 in WB that had been co-IP'd using a CRBN antibody, thereby helping to demonstrate that IKZF3 is a CRNB binding protein (Fig 3D).	WB	Human
Show All 14 Publications. Collapse Publications.

Array NBP2-24495

• Aiolos/IKZF3 Antibodies
• Aiolos/IKZF3 Lysate
• Aiolos/IKZF3 Proteins